Forgot your password ?

 login: 

  Why you need to be registered

 password: 

 Register 

Current issueArchivesubscribeInstructions to Authors

search by
Google





subscribe on the news  

 

Pay Color Illustration
 


Medline

PubMed, a service of the National Library of Medicine

World Oncology Network

R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



Vol. 31, No. 2, 2009 (June)

Content

Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin

 

N.Yu. Lukyanova, N.V. Rusetskya, N.A. Tregubova, V.F. Chekhun

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine, Kyiv 03022, Ukraine

Abstract. Aim: To compare ultrastructure, phenotypic profile and cell cycle progression of MCF-7 human breast cancer cells and MCF7 sublines resistant to cisplatin (MCF-7/DDP) and doxorubicin (MCF-7/DOX). Methods: MTT-test, immunocytochemistry, flow cytometry, electron microscopy. Results: The development of drug resistance to cisplatin and doxorubicin in MCF-7 cells upon the culturing of the initial cells with the raising concentrations of cytostatics was accompanied by the increase in cells adhesion, the increasing differentiation grade and the loss of steroid hormone receptors. Besides, it was shown that antiapoptotic mechanisms (decrease of Bcl-2 expression) and intracellular glutathione detoxifying system are involved in the process of cisplatin resistance deve­lopment in MCF-7 cells. At the same time, P-glycoprotein overexpression in cells resistant to doxorubicin suggests MDR-dependent mechanism. Both doxorubicin- and cisplatin-resistant cells are characterized by the changes in the expression of several cell cycle regulators — Ki-67, cyclin D1, pRb and ð21). Conclusion: The long-time culture of MCF-7 cells with cytostatic drugs results in the decreased cyclin D1, pRb, and Ki-67 expression and increased ð21 expression with the increasing differentiation grade of the resistant cells. The underlying mechanisms of resistance to cisplatin and doxorubicin in MCF-7 cells may be different.

Key Words: drug resistance, cisplatin, doxorubicin, human breast cancer, MCF-7 cells, immunocytochemistry, cell cycle

Language:  English

[full text]




Copyright (c) MORION 1999-2008

Current issue | Archive | subscribe | Instructions to Authors | E-Mail to webmaster